The Philippines' battle against tuberculosis (TB) is a complex and evolving story, and Rugaiya Calapis, an expert from the Department of Health (DOH), offers a fascinating insight into the country's progress and challenges. While the nation has made significant strides in TB control, Calapis highlights the need for increased local investment to ensure the sustainability of these efforts.
One of the most notable advancements is the integration of artificial intelligence (AI) into TB detection. By utilizing AI-equipped chest x-ray vans, the Philippines has significantly reduced diagnostic delays. This technology enables rapid identification of TB, even in areas lacking radiologists, which was a previous bottleneck. The use of AI not only speeds up the process but also improves accuracy, allowing for earlier intervention and potentially better patient outcomes.
The country has also made strides in treating drug-resistant TB, a formidable foe in the fight against the disease. New treatment regimens have shortened the duration of therapy from 20 months to just six months, a remarkable achievement. This reduction in treatment time not only improves patient compliance but also reduces the likelihood of further drug resistance.
Calapis emphasizes the importance of training primary healthcare workers and community-based partners. By equipping these individuals with the skills to provide the 'entire cascade of care' for TB patients, the country aims to ensure that treatment is accessible and efficient, even at the initial stages of diagnosis. This approach empowers local healthcare systems and fosters a more proactive approach to TB management.
However, despite these impressive gains, the Philippines still faces significant challenges. In 2025, it was ranked as the third-most burdened country by TB, accounting for 6.8% of global cases. Calapis attributes this to increased testing and reporting, which is a positive development but also highlights the need for sustained investment. The country's TB control program relies heavily on international funding, and a reduction in support could lead to delayed diagnoses, incomplete treatments, and a resurgence of the disease.
One area for improvement, according to Calapis, is multi-disease testing. This approach, where a patient's specimen is tested for multiple illnesses, can reduce costs and improve efficiency. However, it requires a robust specimen transportation system, which may be a challenge to implement. Additionally, raising awareness among the Filipino population remains a crucial task. Despite the National TB Control Program's longevity, there is still a gap in awareness, with many patients seeking treatment at late stages due to a lack of understanding about the disease's severity.
In conclusion, the Philippines' journey in combating TB is a testament to the power of innovation and collaboration. While significant progress has been made, Calapis' insights underscore the importance of continued investment and awareness. By addressing these challenges, the country can build a more resilient and sustainable healthcare system, ensuring that TB remains a manageable threat rather than an insurmountable burden.
